Navigation Links
Valeant Pharmaceuticals Provides Update to Recent Event
Date:4/4/2013

/p>

Forward Looking Statements

This press release contains forward-looking statements regarding, among other things, the ability of our business model to deal with unexpected events, the launch of our authorized generic of Zovirax ointment, the financial impact of the genericization of Zovirax ointment, and our 2013 performance.  Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements.  Because these statements reflect Valeant's current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could cause actual results to differ materially from those expressed in forward-looking statements contained in this press release. These factors include, but are not limited to the market acceptance of our authorized generic Zovirax ointment, the impact of the genericization of Zovirax ointment and other risks and uncertainties, including those detailed from time to time in Valeant's periodic reports filed with the Securities and Exchange Commission ("SEC") and the Canadian Securities Administrators ("CSA"), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption "RISK FACTORS" in Valeant's annual reports on Form 10-K for the year ended December 31, 2012, which have been filed with the SEC and the CSA. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause Valeant's actual results to differ materially from expected and historical results. Valeant assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Contact Information:


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals And Obagi Medical Products Agree On An Increased Offer Price Of $24.00 Per Share In Cash
2. Valeant Pharmaceuticals Announces Private Exchange Offer
3. Valeant Pharmaceuticals International, Inc. Agrees to Acquire Obagi Medical Products, Inc. for $19.75 Per Share in Cash
4. Valeant Pharmaceuticals Reports 2012 Fourth Quarter Financial Results
5. Valeant Completes Acquisition Of Natur Produkt In Russia
6. Valeant Pharmaceuticals To Announce 2012 Fourth Quarter Results On February 28, 2013
7. Valeant Completes Acquisition of Medicis and Announces Date of 2013 Financial Guidance Conference Call
8. Valeant Pharmaceuticals And Galderma Agree On Revised Agreement Terms
9. Valeant Pharmaceuticals Announces New Management Appointments
10. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
11. Valeant Pharmaceuticals Annonces New $1.5 Billion Securites Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... visión holística de l cuidado al ... trayecto   Royal Philips  ... debut europeo de IntelliSpace Cardiovascular , un sistema ... sofisticadas herramientas para acceder, analizar y compartir imágenes cardiovasculares ...
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3CytomX Files Registration Statement for Proposed Initial Public Offering 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... and development of drugs for the treatment of human ... fourth quarter and year ended December 31, 2011 as ... (HCV) development pipeline. Operational HighlightsIDX184 ...
... Psychemedics Corporation (NASDAQ: PMD ) today announced ... December 31, 2011.  The Company also announced an increase in ... of record as of March 5, 2012 to be paid ... consecutive quarterly dividend. The Company,s revenue for the ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 2Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 3Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 4Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 5
(Date:8/31/2015)... ... August 31, 2015 , ... Now through October 31st, the ... be featured on a digital screen projected above New York’s Times Square, on ... promote earlier awareness of the symptoms of ovarian cancer, and earlier conversations with ...
(Date:8/31/2015)... ... ... All birth control methods work best if used correctly every time you have ... Moreover, no-scalpel vasectomy has many proven advantages with a lower complication rate over the ... are afraid of complications. , One Stop Medical Center reported a zero failure ...
(Date:8/31/2015)... ... ... TheHardwareCity.com is pleased to announce the availability of the technologically-advanced and easy ... are manufactured by Allied Tools. The set consists of a selection of basic tools ... and house work to be completed easily and efficiently without the sacrifice of power ...
(Date:8/30/2015)... ... August 31, 2015 , ... Although middle market companies ... issues that are critically important to them are often overlooked when government sets ... proposed legislation and changing tax and regulatory policies. Smaller companies, which often suffer ...
(Date:8/30/2015)... IL (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected ... this exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
Breaking Medicine News(10 mins):Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 2Health News:National Ovarian Cancer Coalition Rolls Out "TAKE ACTION. NOT CHANCES. (SM)" Campaign for September, National Ovarian Cancer Awareness Month 3Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:TheHardwareCity.com Now Offering Allied 49032 25 Piece Tri-Fold Tool Set 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 2Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 3Health News:Newport Board Group, an Advisory Firm Serving the Middle Market, Issues Five Tips on Selling Services to the Government 4Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3
... in the treatment of intestinal disorders for close to ... to be extended to people with rectal cancer. In ... or "hand-assisted" laparoscopic surgery for rectal cancer, a team ... Medical Center has shown that the minimally invasive approach ...
... Nov. 10 Reportlinker.com announces that a ... its catalogue. , Central Nervous ... , http://www.reportlinker.com/p0161866/Central-Nervous-System-Insomnia-or-Sleep-Disorders.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire , ... or Sleep Disorders contains detailed information on ...
... at Kickoff Event , HARRISBURG, Pa., Nov. 10 ... in Pennsylvania by urging students to build a rewarding ... , "There will be rising demand for many ... seven years," said Governor Rendell. "During Health Careers Week, ...
... Texas Health Presbyterian Hospital Dallas is the first hospital in ... be named a Cycle III Chest Pain Center by the ... heart attack treatment. , "This honor means that Texas Health ... rapid recognition and collaborative treatment of heart attacks," said cardiologist ...
... Mayo Clinic research studied the association between prostate-specific antigen (PSA) ... of prostate growth is not necessarily a predictor for the ... a man,s PSA level is rising quickly, a prostate biopsy ... findings are being presented this week at the ...
... Medical School estimates 2,266 U.S. military veterans under the age of ... had reduced access to care. That figure is more than 14 ... Afghanistan in 2008, and more than twice as many as have ... 2001. The researchers, who released their analysis today, pointedly say ...
Cached Medicine News:Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 2Health News:Minimally invasive surgery shown safe and effective treatment for rectal cancer 3Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 2Health News:Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders 3Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 2Health News:PA Governor Rendell Puts Focus of Health Careers Week on In-Demand Occupations 3Health News:Texas Health Dallas Receives Prestigious Chest Pain Accreditation 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 2Health News:Routine Evaluation of Prostate Size Not as Effective in Cancer Screening, Mayo Study Finds 3Health News:Over 2,200 veterans died in 2008 due to lack of health insurance 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: